Envarsus Neurotoxicity Burden in Liver Transplant Patients
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This study will compare neurologic side effects associated with two immunosuppressant
medications used in liver transplant patients. The standard therapy of twice daily immediate
release Tacrolimus will be compared to Envarsus once daily. We hypothesize that Envarsus will
show a lower rate of neurologic side effects than immediate release tacrolimus.